R
Ruediger Edward H
Researcher at Bristol-Myers Squibb
Publications - 60
Citations - 1493
Ruediger Edward H is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Hepatitis C virus & Hydroxymethyl. The author has an hindex of 18, co-authored 60 publications receiving 1458 citations. Previous affiliations of Ruediger Edward H include Université de Montréal.
Papers
More filters
Patent
Hepatitis C virus inhibitors
Carol Bachand,Makonen Belema,Deon Daniel H,Andrew C. Good,Goodrich Jason,James Clint A,Lavoie Rico,Lopez Omar D,Alain Martel,Nicholas A. Meanwell,Van N. Nguyen,Jeffrey L. Romine,Ruediger Edward H,Lawrence B. Snyder,Denis R. St. Laurent,Fukang Yang,David R. Langley,Gan Wang,Lawrence G. Hamann +18 more
TL;DR: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection as mentioned in this paper, and also disclosed are pharmaceutical compositions containing such compounds and methods to use these compounds in the treatment.
Patent
Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
Guixue Yu,Macor John E,Timothy F. Herpin,R. Michael Lawrence,Morton George C,Rejean Ruel,Graham S. Poindexter,Ruediger Edward H,Carl Thibault +8 more
TL;DR: In this paper, the authors defined a set of compounds having the formula (I), and pharmaceutically acceptable salts, hydrates and prodrugs thereof, in which E is formula (II), X is N or CH, W is -NR16R17, -NR 16C(=O)R22, NR16CO2R22 and -OR23, or a heteroaryl or heterocyclo group as defined in the specification.
Journal ArticleDOI
The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization
Dike Qiu,Julie A. Lemm,Donald R. O'Boyle,Jin-Hua Sun,Peter T. Nower,Van N. Nguyen,Lawrence G. Hamann,Lawrence B. Snyder,Deon Daniel H,Ruediger Edward H,Nicholas A. Meanwell,Makonen Belema,Min Gao,Robert A. Fridell +13 more
TL;DR: It is reported that an NS5A inhibitor impaired hyperphosphorylation without affecting basal phosphorylation at the C-terminal region ofNS5A, which may help to explain the exceptional potency of this class of HCV replication complex inhibitors.
Journal ArticleDOI
Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.
Makonen Belema,Van N. Nguyen,Carol Bachand,Deon Daniel H,Goodrich Jason,James Clint A,Lavoie Rico,Lopez Omar D,Alain Martel,Jeffrey L. Romine,Ruediger Edward H,Lawrence B. Snyder,Denis R. St. Laurent,Fukang Yang,Juliang Zhu,Henry S. Wong,David R. Langley,Stephen P. Adams,Glenn H. Cantor,Anjaneya Chimalakonda,Aberra Fura,Benjamin M. Johnson,Jay O. Knipe,Dawn D. Parker,Kenneth S. Santone,Robert A. Fridell,Julie A. Lemm,Donald R. O'Boyle,Richard J. Colonno,Min Gao,Nicholas A. Meanwell,Lawrence G. Hamann +31 more
TL;DR: Clinical proof-of-concept for the NS5A replication complex inhibitor class, and regulatory approval to market it with the NS3/4A protease inhibitor asunaprevir for the treatment of HCV genotype-1b infection has recently been sought in Japan.
Journal ArticleDOI
Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors.
Francis Beaulieu,Carl Ouellet,Ruediger Edward H,Makonen Belema,Yuping Qiu,Xuejie Yang,Jacques Banville,James R. Burke,Kurt R. Gregor,John F. MacMaster,Alain Martel,Kim W. McIntyre,Mark A. Pattoli,F. Christopher Zusi,Dolatrai M. Vyas +14 more
TL;DR: In order to further explore the SAR around the imidazoquinoxaline tricyclic structure of 1, a series of tetracyclic analogues are prepared and the synthesis and biological activities of these potent IKK inhibitors are described.